Total
0
Shares
MGC Pharma (ASX:MXC) - Co Founder and Managing Director, Roby Zomer - The Market Herald
Co Founder and Managing Director, Roby Zomer
Source: FinFeed
  • MGC Pharmaceuticals (MXC) has received an 85 per cent increase in its January order volume over the past week
  • In just one week, orders for the biopharma's Mercury Pharma products have increased from 2000 to 3700 units
  • The Mercury Pharma brand launched last month and was developed to deliver cost-effective cannabidiol medicines
  • The company expects the increased orders will deliver over $430,000 in short term revenue
  • MGC Pharma is up a slight 1.85 per cent with shares trading for 2.8 cents each

MGC Pharmaceuticals (MXC) has received an 85 per cent increase to its January purchase order volume over the past week.

In just one week, the biopharma company's orders have increased from 2000 to 3700 units for the immediate production and delivery of its Mercury Pharma line of prescription products.

The Mercury Pharma brand launched last month. It was developed to deliver a cost-focused medicine for Australian and New Zealand patients. In such a small time frame it has already received strong patient demand.

The first product of the brand was the MP100 — a 100mg/ml cannabidiol (CBD) solution.

The increased 3,700 unit order for Mercury Pharma and white-label products will deliver over $430,000 in short term revenue.

All products will be prescribed by health care professionals in Australia and New Zealand, distributed by Australian specialist Cannvalate, and several other distribution partners in New Zealand.

"Upon delivery to patients in the coming weeks, we will see a more than doubling of current total MGC Pharma medicines prescribed to date to over 4500, which we expect to grow rapidly over the coming months," Co-founder and Managing Director Roby Zomer said.

MGC Pharma is up a slight 1.85 per cent with shares trading for 2.8 cents each at 12:16 pm AEDT.


Subscribe


MXC by the numbers
More From The Market Herald
OBJ (ASX:OBJ) - CEO, Paul Peros - The Market Herald

" OBJ (ASX:OBJ) to raise $4.5M for product development and licencing

Innovative wellness company OBJ (OBJ) is aiming to raise $4.5 million through an entitlement offer and placement for licencing, development and general workin…
Creso Pharma (ASX:CPH) - CEO & Co Founder, Dr Miri Halperin Wernli (left) and Chairman, Boaz Wachtel (right) - The Market Herald

" Creso Pharma (ASX:CPH) subsidiary receives follow-up order from Univo Pharmaceuticals

Creso Pharma’s (CPH) subsidiary, Mernova Medicinal, has received a US$625,690 (roughly A$901,830) purchase order from Univo Pharmaceuticals.
Holista Colltech (ASX:HCT) - Managing Director, Dr Rajen Manicka - The Market Herald

" Holista CollTech (ASX:HCT) misses the mark for hand sanitiser product

Holista CollTech (HCT) has downgraded its $3.8 million in expected sales from its hand sanitiser product, Natshield, due to COVID-19 and race riots.
Cellmid (ASX:CDY) - CEO, Maria Halasz (right) - The Market Herald

" Cellmid (ASX:CDY) signs distribution agreement for SARS-CoV-2 and ELISA’s

Cellmid (CDY) has signed a distribution agreement with Immunodiagnostics (IMD) for Enzyme Linked Immunosorbent Assays (ELISA’s) and SARS-CoV-2 tests in Australia and New